WPI 845 (Glipizide extended release 10 mg)
Pill imprint WPI 845 has been identified as Glipizide extended release 10 mg.
Glipizide is used in the treatment of diabetes, type 2 and belongs to the drug class sulfonylureas. Risk cannot be ruled out during pregnancy. Glipizide 10 mg is not a controlled substance under the Controlled Substance Act (CSA).
- WPI 845
- 10 mg
- 6.00 mm
- Prescription only
- Drug Class:
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Watson Laboratories, Inc.
- National Drug Code (NDC):
- Inactive Ingredients:
- acetyltributyl citrate
hydroxyethyl cellulose (2000 mpa.s at 1%)
hydroxypropyl cellulose (type h)
methacrylic acid - methyl methacrylate copolymer (1:1)
|NDC Code||Manufacturer / Repackager|
|68084-0112||Amerisource Health Services|
|10370-0191||Anchen Pharmaceuticals, Inc|
|54569-5548||A-S Medication Solutions, LLC (repackager)|
|54868-4988||Physicians Total Care Inc (repackager)|
|55289-0301||PDRX Pharmaceuticals Inc (repackager)|
Note: Inactive ingredients may vary.
More about glipizide
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.